Abstract
In this multicenter retrospective cohort study of over 1 million patients at 150 US hospitals, proton pump inhibitors increased the odds of a patient having hospital-onset Clostridium difficile infection as did third and fourth generation cephalosporins, carbapenems, and piperacillin/tazobactam. These findings support appropriate prescribing of acid-suppression therapy and high-risk antibiotics.
Publication types
-
Evaluation Study
-
Multicenter Study
MeSH terms
-
Anti-Bacterial Agents / adverse effects*
-
Anti-Bacterial Agents / therapeutic use
-
Carbapenems / adverse effects*
-
Carbapenems / therapeutic use
-
Clostridioides difficile / isolation & purification
-
Clostridium Infections / epidemiology*
-
Cross Infection / epidemiology*
-
Cross Infection / microbiology
-
Female
-
Hospitals
-
Humans
-
Male
-
Odds Ratio
-
Proton Pump Inhibitors / adverse effects*
-
Retrospective Studies
-
Risk Factors
-
United States / epidemiology
-
Young Adult
Substances
-
Anti-Bacterial Agents
-
Carbapenems
-
Proton Pump Inhibitors